evotec_Nov23_PanOmicsDriven - 40

The PanHunter Platform
sion showed a slightly better survival rate. However,
PanHunter pointed out that the correlation observed
here was not significant (p-value = 0.137).
As there are often gender-specific differences
in cancer, both sub-cohorts were filtered subsequently,
again via a quick GUI setting to leave only
male patients selected. As a result, the survival
plot (Figure 10) was updated on-the-fly and a much
stronger difference for high vs. low REG4 expressing
patients became visible, which was now also
statistically significant (p-value = 0.0114). Hence, it
was concluded that REG4 might indeed be a suitable
biomarker to indicate the survival prognosis of colon
adenocarcinoma patients and might help during
diagnosis and assessing treatment responders and
non-responder to drug treatment (which has also
been reported in the literature).
This case-study is one of several case studies that
are also available as demo videos for PanHunter on
YouTube: youtu.be/qdz1lVdC9Io. The entire procedure
from start to finish would take an average user
with the necessary disease-specific knowledge only a
couple of hours when using PanHunter.
All shown plots are taken directly from
PanHunter, were generated on-the-fly, and no
external/additional tools were needed.
Evotec strongly believes in the power of omics-driven drug
discovery. The unbiased nature and magnitude of insight enabled
by multi-omics will allow us to tackle the challenges ahead.
[click for more info]
40
GENengnews.com

https://www.youtube.com/watch?v=qdz1lVdC9Io https://www.youtube.com/watch?v=qdz1lVdC9Io https://panhunter.com/panhunter-generating-multi-omics-insights/ https://www.genengnews.com https://www.genengnews.com

evotec_Nov23_PanOmicsDriven

Table of Contents for the Digital Edition of evotec_Nov23_PanOmicsDriven